Le Lézard6h
MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...
Healio20h
Stem cell transplant suppresses relapse in multiple sclerosis up to 4 years
Among individuals from the United Kingdom with multiple sclerosis, autologous hematopoietic stem cell transplantation led to significant relapse suppression up to 4 years, according to a ...
Adia Nutrition Inc. Completes Independent Audit with Astra Audit and Advisory LLC., Prepares to File for OTCQB Uplisting
Adia Nutrition Inc. (OTC Pink: ADIA), a pioneering force in advanced stem cell therapies and nutritional wellness, is proud ...